# Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients

> **NCT00857324** · PHASE1,PHASE2 · TERMINATED · sponsor: **Tiziana Marangon** · enrollment: 18 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT00857324
- **Lead sponsor:** Tiziana Marangon
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03
- **Primary completion:** 2012-03
- **Final completion:** 2017-05
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** The Phase I of the study was completed, but Phase 2 has not been activated
- **Last updated:** 2017-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00857324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00857324, "Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00857324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*